Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

Gil-Jimenez, Alberto; van Dorp, Jeroen; Contreras-Sanz, Alberto; van der Vos, Kristan; Vis, Daniel J; Braaf, Linde; Broeks, Annegien; Kerkhoven, Ron; van Kessel, Kim E M; Ribal, María José; Alcaraz, Antonio; Wessels, Lodewyk F A; Seiler, Roland; Wright, Jonathan L; Mengual, Lourdes; Boormans, Joost; van Rhijn, Bas W G; Black, Peter C; van der Heijden, Michiel S (2022). Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. (In Press). European urology Elsevier 10.1016/j.eururo.2022.07.023

[img] Text
1-s2.0-S0302283822025386-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (439kB) | Request a copy

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in ERBB2, and alterations in ATM, RB1, and FANCC are correlated with pathological response to NAC in MIBC. The objective of this study was to validate these genomic biomarkers in pretreatment transurethral resection material from an independent retrospective cohort of 165 patients with MIBC who subsequently underwent NAC and radical surgery. Patients with ypT0/Tis/Ta/T1N0 disease after surgery were defined as responders. Somatic deleterious mutations in ERCC2 were found in nine of 68 (13%) evaluable responders and two of 95 (2%) evaluable nonresponders (p = 0.009; FDR = 0.03). No correlation was observed between response and alterations in ERBB2 or in ATM, RB1, or FANCC alone or in combination. In an exploratory analysis, no additional genomic alterations discriminated between responders and nonresponders to NAC. No further associations were identified between the aforementioned biomarkers and pathological complete response (ypT0N0) after surgery. In conclusion, we observed a positive association between deleterious mutations in ERCC2 and pathological response to NAC, but not overall survival or recurrence-free survival. Other previously reported genomic biomarkers were not validated. PATIENT SUMMARY: It is currently unknown which patients will respond to chemotherapy before definitive surgery for bladder cancer. Previous studies described several gene mutations in bladder cancer that correlated with chemotherapy response. This study confirmed that patients with bladder cancer with a mutation in the ERCC2 gene often respond to chemotherapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

UniBE Contributor:

Seiler-Blarer, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0302-2838

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

17 Aug 2022 14:50

Last Modified:

17 Aug 2022 14:58

Publisher DOI:

10.1016/j.eururo.2022.07.023

PubMed ID:

35965206

Uncontrolled Keywords:

Cisplatin-based chemotherapy DNA sequencing Muscle-invasive bladder cancer Neoadjuvant chemotherapy Response prediction Somatic mutations

BORIS DOI:

10.48350/172047

URI:

https://boris.unibe.ch/id/eprint/172047

Actions (login required)

Edit item Edit item
Provide Feedback